Overview
India Globalization Capital (IGC) reports its Phase II CALMA trial investigating a cannabinoid-based therapy for Alzheimer’s disease is 70% enrolled and on track for mid-year completion, alongside the upcoming beta launch of its MINT-AD artificial intelligence platform for Alzheimer’s detection. These developments represent meaningful progress in the clinical investigation of cannabinoid therapeutics for neurodegenerative disease, an area where preclinical data on neuroinflammation and amyloid pathology has long warranted rigorous human trials.
Clinical Perspective
The Phase II CALMA trial investigating a cannabinoid-based therapeutic for Alzheimer’s disease is now 70% enrolled, with top-line data anticipated by mid-year — and this deserves our attention. For years, we’ve had compelling preclinical evidence that cannabinoids may modulate neuroinflammation, reduce amyloid-beta aggregation, and offer neuroprotective benefits, but what we’ve lacked is robust human trial data.
🔬 Phase II CALMA trial on track for mid-year completion with meaningful enrollment progress
🧠 MINT-AD AI platform approaching beta launch, potentially improving early Alzheimer’s detection
🔬 Favorable regulatory environment continues to open doors for cannabinoid clinical research
🧠 This is the evidence-based pathway that legitimizes cannabinoid therapeutics in neurodegenerative care
Whether or not this specific compound succeeds, every well-designed cannabinoid trial strengthens the scientific foundation our field needs to move from anecdote to evidence.
Have thoughts on this? Share it: